# Lymphoma, Large B-Cell, Diffuse trials: 169 new

Updated November 5, 2026.

169 clinical studies in Lymphoma, Large B-Cell, Diffuse were first posted on ClinicalTrials.gov from November 12, 2024 to November 5, 2026; 46 have an industry sponsor and 146 are recruiting or about to. The newest, NCT07917754, was posted on November 5, 2026: A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma... (Merck Sharp & Dohme LLC).

## The full list

New Lymphoma, Large B-Cell, Diffuse clinical trials: 169 rows for $8.45, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 8 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/lymphoma-large-b-cell-diffuse

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 169
- Industry sponsored: 46
- Recruiting or not yet: 146
- Latest posted: November 5, 2026

## Newest trials

The newest 100 of 169, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07917754 | A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Merck Sharp & Dohme LLC | Phase 2/3 | Not yet recruiting | Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | 470 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917754) |
| November 4, 2026 | NCT07917624 | Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 87 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917624) |
| November 2, 2026 | NCT07908888 | Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in... | The First Hospital of Jilin University | Phase 4 | Recruiting | Diffuse Large B-Cell Lymphoma | 26 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908888) |
| October 30, 2026 | NCT07906080 | Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK\_D332) in Combination With Tafasitamab and... | Istituto Oncologico Veneto IRCCS | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 14 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906080) |
| October 23, 2026 | NCT07892027 | Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma... | University of Michigan Rogel Cancer Center | Phase 2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma... | 26 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892027) |
| October 21, 2026 | NCT07887750 | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887750) |
| October 21, 2026 | NCT07887646 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell... | BeOne Medicines | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, B-cell Malignancies | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887646) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | GUSTAVO SALGUERO | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| October 19, 2026 | NCT07881211 | A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell... | BeOne Medicines | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, B-Cell Malignancies | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881211) |
| October 16, 2026 | NCT07878351 | Prospective ctDNA Testing in Large B-Cell Lymphoma | Peking University People's Hospital | Observational | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878351) |
| October 15, 2026 | NCT07875413 | Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell... | AbelZeta Inc. | Phase 2 | Not yet recruiting | Large B Cell Lymphoma, LBCL, Diffuse Large B Cell Lymphoma (DLBCL), Relapse Diffuse Large B Cell Lymphoma, High Grade B... | 55 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875413) |
| October 7, 2026 | NCT07862764 | A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell... | AbbVie | Observational | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 175 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862764) |
| September 14, 2026 | NCT07818499 | A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 204 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818499) |
| September 14, 2026 | NCT07817641 | Proton Therapy for Mediastinal Lymphoma (PROMLY) | Copenhagen University Hospital, Rigshospitalet | Not applicable | Recruiting | Mediastinal Lymphoma, Hodgkin Disease Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | 139 | Denmark | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07817641) |
| September 10, 2026 | NCT07814170 | A Manualised Post-Traumatic Growth Intervention For People With Hematological Cancers In Greece | University of West Attica | Not applicable | Active not recruiting | Blood Cancers, Leukemia, Lymphoma, Bone Marrow Transplant, Psychological Trauma, Neoplasms, Hematological Malignancies... | 80 | Greece | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814170) |
| September 10, 2026 | NCT07814001 | Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL), Refractory... | 55 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814001) |
| September 9, 2026 | NCT07808827 | A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients... | Shanghai Junshi Bioscience Co., Ltd. | Phase 3 | Recruiting | Diffuse Large B-Cell Lymphoma | 282 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07808827) |
| September 4, 2026 | NCT07804173 | Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas | Sohag University | Observational | Not yet recruiting | Diffuse Large B-cell Lymphoma and Aggressive B-cell Lymphomas | 70 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07804173) |
| August 26, 2026 | NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1/2 | Recruiting | Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large... | 70 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788118) |
| August 19, 2026 | NCT07774234 | Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Large B-Cell Lymphoma (LBCL), High-grade B-cell Lymphoma | 39 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07774234) |
| August 14, 2026 | NCT07764601 | R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma | WEI XU | Not applicable | Not yet recruiting | Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma | 58 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764601) |
| August 13, 2026 | NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell... | 59 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763210) |
| August 12, 2026 | NCT07760610 | Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line Response | The First Hospital of Jilin University | Phase 4 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 27 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07760610) |
| August 6, 2026 | NCT07750886 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) | Natera, Inc. | Observational | Recruiting | Non-Hodgkin Lymphoma, T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma, Primary Mediastinal... | 200 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07750886) |
| August 6, 2026 | NCT07749976 | GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors | Vitruviae | Phase 1/2 | Not yet recruiting | Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome, Solid Tumor... | 108 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749976) |
| August 5, 2026 | NCT07748364 | Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics | Joshua Brody | Phase 2 | Not yet recruiting | Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma | 16 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748364) |
| July 30, 2026 | NCT07735533 | A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies | Umoja Biopharma | Phase 1/2 | Recruiting | Lymphoma, B Cell, Lymphoma Non-Hodgkin, High Grade B Cell Lymphoma, Richter Transformation Lymphoma, Grade 3b... | 274 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07735533) |
| July 27, 2026 | NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30) | The Methodist Hospital Research Institute | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), Anaplastic Large Cell... | 21 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729397) |
| July 24, 2026 | NCT07725406 | Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma | Weill Medical College of Cornell University | Phase 1 | Recruiting | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07725406) |
| July 20, 2026 | NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients | Jonsson Comprehensive Cancer Center | Phase 1 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large... | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714421) |
| July 20, 2026 | NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Kure Cells, INC | Phase 2 | Not yet recruiting | Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell... | 105 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713459) |
| July 17, 2026 | NCT07712588 | Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) | Dizal Pharmaceuticals | Phase 2/3 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 880 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07712588) |
| July 14, 2026 | NCT07702851 | A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After... | Yonsei University | Phase 2 | Not yet recruiting | Diffuse Large B-cell Lymphoma | 47 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07702851) |
| July 9, 2026 | NCT07691606 | A Study of ARC-02 in B-cell NHL | Taiho Oncology, Inc. | Phase 1 | Recruiting | B-cell Non Hodgkin Lymphoma | 140 | Australia, France, Italy, Poland, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07691606) |
| June 30, 2026 | NCT07676877 | Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent... | Nathan Denlinger | Phase 1 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07676877) |
| June 25, 2026 | NCT07669194 | Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Observational | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07669194) |
| June 17, 2026 | NCT07654426 | The CARDIOPROTECT Trial | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654426) |
| June 17, 2026 | NCT07652476 | Neurocognitive Assessment in Long-Term Survivors of Lymphoma | Fondazione Italiana Linfomi - ETS | Observational | Not yet recruiting | Classic Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal B Cell Lymphoma | 100 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07652476) |
| June 16, 2026 | NCT07649304 | AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") | National Cancer Institute (NCI) | Phase 1 | Recruiting | AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07649304) |
| June 10, 2026 | NCT07638982 | Axatilimab + CAR-T for High-Risk Lymphoma | Northside Hospital, Inc. | Phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell... | 29 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638982) |
| June 8, 2026 | NCT07634289 | Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma | Olivia Newton-John Cancer Research Institute | Phase 2 | Not yet recruiting | Relapsed /Refractory DLBCL | 40 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634289) |
| June 2, 2026 | NCT07621406 | Efficacy and Safety of Sequential Autologous Hematopoietic Stem Cell Transplantation Combined With Tafasitamab, Lenalidomide, and Standard... | The First Affiliated Hospital of Soochow University | Phase 2 | Active not recruiting | Relapsed/Refractory Diffuse Large B Cell Lymphoma | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621406) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| May 27, 2026 | NCT07608978 | Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608978) |
| May 22, 2026 | NCT07601607 | Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 51 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601607) |
| May 20, 2026 | NCT07599423 | A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | The First Affiliated Hospital of Soochow University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 96 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07599423) |
| May 15, 2026 | NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | Carrie Ho, MD | Phase 2 | Not yet recruiting | Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin, Diffuse Large B-Cell Lymphoma (DLBCL) | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07588698) |
| May 13, 2026 | NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | Chipscreen Biosciences, Ltd. | Phase 1 | Not yet recruiting | Pancreatic Adenocarcinoma, Non Small Cell Lung Cancer, Advanced Solid Tumors, Lymphoma, Diffuse Large B-Cell Lymphoma... | 186 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583771) |
| April 20, 2026 | NCT07539688 | Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell Lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 | Not yet recruiting | Relapsed/Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma, Inert B-cell Lymphoma Transformed Into Large B-cell... | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07539688) |
| April 14, 2026 | NCT07528352 | External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL | University of Utah | Phase 1 | Recruiting | Diffuse Large B Cell Lymphoma | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07528352) |
| April 13, 2026 | NCT07523737 | Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell... | Beijing Tongren Hospital | Phase 2 | Recruiting | Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) | 43 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523737) |
| April 9, 2026 | NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008) | Merck Sharp & Dohme LLC | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse | 280 | Argentina, Australia, Brazil, Canada, Chile, China, France, Germany, Israel... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519772) |
| April 8, 2026 | NCT07517705 | MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma | University of Nebraska | Phase 2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma | 50 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517705) |
| April 2, 2026 | NCT07507318 | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission | Rong Tao | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma | 69 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07507318) |
| March 31, 2026 | NCT07502872 | TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma | Brown University | Phase 2 | Not yet recruiting | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502872) |
| March 30, 2026 | NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) | Health Institutes of Turkey | Phase 2/3 | Recruiting | Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma, Diffuse... | 40 | Turkey (Türkiye) | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502118) |
| March 30, 2026 | NCT07499271 | Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 35 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07499271) |
| March 27, 2026 | NCT07494565 | Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL | Sun Yat-sen University | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494565) |
| March 25, 2026 | NCT07493486 | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study | Zhejiang Cancer Hospital | Phase 2 | Completed | Diffuse Large B-Cell Lymphoma (DLBCL), Intrathecal Chemotherapy | 31 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493486) |
| March 25, 2026 | NCT07493148 | Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL | Ou Bai, MD/PHD | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493148) |
| March 25, 2026 | NCT07493109 | Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP | Ou Bai, MD/PHD | Phase 3 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07493109) |
| March 24, 2026 | NCT07489989 | Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. | Daihong Liu | Phase 2 | Recruiting | Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489989) |
| March 18, 2026 | NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Active not recruiting | Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | 40 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480850) |
| March 18, 2026 | NCT07478848 | Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma... | 14 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478848) |
| March 17, 2026 | NCT07476105 | Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment | Fondazione Italiana Linfomi - ETS | Not applicable | Not yet recruiting | Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B | 170 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07476105) |
| March 16, 2026 | NCT07473167 | Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients | TICAROS Co., Ltd. | Phase 1/2 | Recruiting | Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), High-grade... | 98 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473167) |
| March 11, 2026 | NCT07463781 | Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy | Fondazione Italiana Linfomi - ETS | Observational | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), High Grade B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma (PMBCL) | 100 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07463781) |
| March 5, 2026 | NCT07451652 | Low Dose Epcoritamab Plus GemOx in R/R DLBCL | Hospital Universitario Dr. Jose E. Gonzalez | Phase 2 | Recruiting | Relapsed/Refractory Diffuse Large B Cell Lymphoma | 10 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07451652) |
| March 2, 2026 | NCT07443514 | Cognitive Impairment in Patients With Diffuse Large B-Cell Lymphoma | Institute of Oncology Ljubljana | Not applicable | Recruiting | Diffuse Large B-Cell Lymphoma | 3 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07443514) |
| February 20, 2026 | NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Ascentage Pharma Group Inc. | Phase 1 | Recruiting | Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic... | 180 | China, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424833) |
| February 17, 2026 | NCT07412405 | This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells... | GUSTAVO SALGUERO | Not applicable | Not yet recruiting | Adult B-cell Acute Lymphoblastic Leukemia, Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell... | 12 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412405) |
| February 13, 2026 | NCT07409428 | A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL | Hutchmed | Phase 3 | Recruiting | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | 240 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409428) |
| February 10, 2026 | NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | Sun Yat-sen University | Phase 1/2 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 122 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07398638) |
| February 9, 2026 | NCT07397832 | CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 58 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397832) |
| February 6, 2026 | NCT07393204 | Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL | Andrés José Maria Ferreri | Observational | Active not recruiting | Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma | 150 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07393204) |
| January 28, 2026 | NCT07371923 | Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma | Beijing Tongren Hospital | Phase 2 | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 50 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07371923) |
| January 26, 2026 | NCT07368270 | Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Diffuse Large B Cell Lymphoma | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07368270) |
| January 26, 2026 | NCT07365306 | Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment... | City of Hope Medical Center | Phase 2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise... | 43 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365306) |
| January 16, 2026 | NCT07348575 | A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse... | Second Affiliated Hospital of Nanchang University | Phase 3 | Enrolling by invitation | Lymphoma, Large-Cell, Diffuse | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07348575) |
| December 30, 2025 | NCT07310186 | Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy | Peking Union Medical College Hospital | Observational | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 200 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07310186) |
| December 16, 2025 | NCT07284433 | Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies | AvenCell Therapeutics, Inc. | Phase 1/2 | Recruiting | Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy | 178 | Germany, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284433) |
| December 3, 2025 | NCT07260812 | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | TCRx Therapeutics Co.Ltd | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260812) |
| November 28, 2025 | NCT07254754 | Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 | Recruiting | DIFFUSE LARGE B-CELL LYMPHOMA | 45 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254754) |
| November 12, 2025 | NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | France, Germany, Italy, Japan, Poland, Spain, United Kingdom, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226843) |
| November 10, 2025 | NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in... | Genmab | Phase 3 | Active not recruiting | Diffuse Large B-Cell Lymphoma | 72 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226752) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Paolo Caimi, MD | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| October 14, 2025 | NCT07215832 | Karyopharm Expanded Access Program for Selinexor | Karyopharm Therapeutics Inc | Not applicable | Available | Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma, Peripheral T-cell Lymphoma... | Not listed |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07215832) |
| October 1, 2025 | NCT07200375 | An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma | Hoffmann-La Roche | Observational | Recruiting | Diffuse Large B-Cell Lymphoma | 300 | China, Hong Kong | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07200375) |
| September 30, 2025 | NCT07198230 | Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory... | Ting YANG | Observational | Recruiting | Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07198230) |
| September 29, 2025 | NCT07197307 | Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Universität Münster | Phase 2 | Recruiting | Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B | 120 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197307) |
| September 29, 2025 | NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Recruiting | Solid Tumors, Hematologic Malignancies | 280 | Australia, Belgium, Denmark, Italy, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195916) |
| September 23, 2025 | NCT07189065 | A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 2 | Recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189065) |
| September 23, 2025 | NCT07188558 | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Lyell Immunopharma, Inc. | Phase 3 | Recruiting | Large B-cell Lymphoma, Lymphoma, B-Cell, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin... | 400 | Australia, Canada, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188558) |
| September 23, 2025 | NCT07188077 | Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma | Ting YANG | Observational | Recruiting | Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B-Cell Lymphoma | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188077) |
| September 18, 2025 | NCT07181785 | Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas. | Andrés José Maria Ferreri | Observational | Completed | Diffuse Large B Cell Lymphoma (DLBCL) | 555 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181785) |
| September 11, 2025 | NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | University of Maryland, Baltimore | Phase 1 | Enrolling by invitation | B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular... | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168486) |
| September 11, 2025 | NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | First Affiliated Hospital Xi'an Jiaotong University | Early phase 1 | Not yet recruiting | Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Burkitt Lymphoma | 3 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07168291) |
| September 8, 2025 | NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | First Affiliated Hospital of Zhejiang University | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | 62 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07159906) |
| August 17, 2025 | NCT07126236 | Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large... | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Phase 2 | Recruiting | Large B Cell Lymphoma | 80 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07126236) |
| August 15, 2025 | NCT07124936 | A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Diffuse Large B Cell Lymphoma (DLBCL) | 97 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07124936) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| The First Affiliated Hospital of Soochow University | 6 | August 19, 2026 |
| Sun Yat-sen University | 6 | May 22, 2026 |
| Merck Sharp & Dohme LLC | 4 | November 5, 2026 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 4 | August 26, 2026 |
| Fondazione Italiana Linfomi - ETS | 3 | June 17, 2026 |
| City of Hope Medical Center | 3 | January 26, 2026 |
| Ruijin Hospital | 3 | January 31, 2025 |
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 3 | January 20, 2025 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 | November 4, 2026 |
| The First Hospital of Jilin University | 2 | November 2, 2026 |
| BeOne Medicines | 2 | October 21, 2026 |
| GUSTAVO SALGUERO | 2 | October 20, 2026 |
| AbbVie | 2 | October 7, 2026 |
| Dizal Pharmaceuticals | 2 | July 17, 2026 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 2 | May 27, 2026 |
| Beijing Tongren Hospital | 2 | April 13, 2026 |
| Zhejiang Cancer Hospital | 2 | March 25, 2026 |
| Ou Bai, MD/PHD | 2 | March 25, 2026 |
| Andrés José Maria Ferreri | 2 | February 6, 2026 |
| Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | 2 | November 28, 2025 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 65 | November 4, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 28 | October 30, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 26 | October 16, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 21 | October 21, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 12 | September 14, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 10 | September 9, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 4 | November 5, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 2 | November 2, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 1 | September 11, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 71 | November 4, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 54 | October 23, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 21 | October 30, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 9 | July 9, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 9 | July 9, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 8 | September 10, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 7 | April 9, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 7 | April 9, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 6 | July 9, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 6 | April 9, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 6 | April 9, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 5 | November 12, 2025 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 4 | September 14, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 4 | April 9, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 4 | September 29, 2025 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 3 | September 10, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 3 | April 9, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 3 | April 9, 2026 |
| [Mexico](https://specstream.ai/data/clinical-trials/country/mexico) | 3 | March 5, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 2 | April 9, 2026 |
| [Chile](https://specstream.ai/data/clinical-trials/country/chile) | 2 | April 9, 2026 |
| [Hong Kong](https://specstream.ai/data/clinical-trials/country/hong-kong) | 2 | October 1, 2025 |
| [Portugal](https://specstream.ai/data/clinical-trials/country/portugal) | 2 | February 17, 2025 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 2 | January 7, 2025 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 1 | September 4, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).